ROSEN urges investors in Skye Bioscience to act before Jan. 16, 2026 deadline

Rosen Law Firm — a global investor‑rights law firm — issued a notice Nov. 30, 2025, urging anyone who bought securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025 (the “Class Period”) to consider securing legal counsel before the upcoming January 16, 2026 deadline if they wish to participate or seek lead‑plaintiff status in a pending securities class‑action lawsuit. If you qualify and join the action, you may be eligible for compensation — potentially without paying any out‑of‑pocket fees or costs thanks to a contingency‑fee arrangement. To get involved, the firm directs investors to submit a form via their website, or contact attorney Phillip Kim by phone or email. The lawsuit alleges that during the Class Period, Skye Bioscience made materially false or misleading public statements about the safety, effectiveness, and commercial prospects of its drug candidate nimacimab — overstating its clinical and regulatory chances, which misled investors. When the true information emerged, investors reportedly suffered financial losses. Important caveat: the class has not yet been certified. That means, unless you retain counsel now, you’re not officially represented — though you still have options: you can (1) sign up with a law firm like Rosen, (2) remain an “absent class member” (do nothing for now), or (3) move to be named lead plaintiff before the Jan. 16 deadline. #SkyeBioscience #ClassAction #InvestorRights #RosenLawFirm #SlimScan #GrowthStocks #CANSLIM